Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial

Creative Commons License

Avezum A., Lopes R. D., Schulte P. J., Lanas F., Gersh B. J., Hanna M., ...Daha Fazla

CIRCULATION, cilt.132, sa.8, ss.624-632, 2015 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 132 Sayı: 8
  • Basım Tarihi: 2015
  • Doi Numarası: 10.1161/circulationaha.114.014807
  • Dergi Adı: CIRCULATION
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.624-632
  • Anahtar Kelimeler: apixaban, atrial fibrillation, heart diseases, hemorrhage, oral anticoagulant, stroke, valvular heart disease, DABIGATRAN, RISK, DEATH
  • Ankara Üniversitesi Adresli: Evet

Özet

Background Apixaban is approved for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. However, the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial included a substantial number of patients with valvular heart disease and only excluded patients with clinically significant mitral stenosis or mechanical prosthetic heart valves.